Feasibility study of first-line chemotherapy using Pemetrexed and Bevacizumab for advanced or recurrent nonsquamous non-small cell lung cancer in elderly patients: TORG1015

BACKGROUND: The addition of bevacizumab to cytotoxic agents prolongs survival in patients with nonsquamous non-small cell lung cancer (NSCLC). To date, there is no evidence to suggest that treatment with a cytotoxic agent plus bevacizumab is more effective than a cytotoxic agent alone for nonsquamou...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:BMC Cancer
Egile Nagusiak: Kozuki, Toshiyuki, Nogami, Naoyuki, Kitajima, Hiromoto, Iwasawa, Shunichiro, Sakaida, Emiko, Takiguchi, Yuichi, Ikeda, Satoshi, Yoshida, Masahiro, Kato, Terufumi, Miyamoto, Shingo, Sakamaki, Kentaro, Shinkai, Tetsu, Watanabe, Koshiro
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2016
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4866483/
https://ncbi.nlm.nih.gov/pubmed/27177035
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2338-6
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak